Indeed, T-DXd has demonstrated encouragingactivity in patients with HER2-positive BC that were previously treated withHER2-targeted therapies and chemotherapy, with promising response rates and durableresponses [39].In addition to PD-1/PD-L1inhibitors and ADCs, other immunotherapeutic strategies, such as cancer vaccines andadoptive cell therapy, are also being explored in HER2-positive BC [40][41].Cancer vaccines stimulate the immune system by presenting specific antigens relatedto the HER2 protein, training the immune system to recognize and inhibitHER2-positive cancer cells [42]. The gene discussed is ERBB2; the disease is breast cancer.